Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
U.S. #FDA inspection at #Cipla's manufacturing unit in Patalganga, Maharashtra classified as Voluntary Action Indicated: Exchange Filing.
U.S. #FDA issues establishment inspection report for #AlkemLaboratories manufacturing facility at Baddi.
U.S. FDA inspection at #ShilpaMedicare's Hyderabad bio analytical facility closes with zero observations: Exchange filing
The US FDA has issued six inspectional observations in Form 483 for Cipla's manufacturing facility in Goa. The inspection took place between June 10 to June 21, 2024. Cipla's Goa plant has been under a warning letter since February 2020.
